About Avitide
Avitide is a Healthcare company based in Lebanon (United States) founded in 2012, and was acquired by Repligen in September 2021. Affinity purification solutions are developed for biopharmaceutical applications. Avitide has raised $37.1 million across 8 funding rounds from investors including Orbimed, Repligen and Sands Capital Ventures. Avitide offers products and services including AVIPure Resins and Affinity Purification Platform. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its competitors include Avidity Biosciences, Sutro Biopharma and Vividion Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Avitide was founded in 2012 and is based in Lebanon, United States. Operations focus on the biopharmaceutical sector, where affinity purification solutions are discovered and high-capacity resins are developed for monoclonal antibodies, therapeutic proteins, and recombinant vaccines. Technology access is provided to biopharmaceutical partners, biotechnology firms, and purification product manufacturers via flexible licensing and collaboration arrangements.
- Headquarters Lebanon, United States
- Stage Acquired
- SectorsHealthcare
- Website avitide.com
- Social LinkedIn
- Acquired by Repligen (Sep 2021)
Products & Services of Avitide
Avitide offers a comprehensive portfolio of products and services, including AVIPure Resins and Affinity Purification Platform.
Affinity resins for purifying AAV serotypes with high recovery.
End-to-end platform for biopharmaceutical processing and supply.
Funding Insights of Avitide
Avitide has successfully raised a total of $37.1M across 8 strategic funding rounds. The most recent funding activity was a Series E round of $10 million completed in October 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $37.1M
- Total Rounds 8
- Last Round Series E — $10M
- First Round $1.45M
(Mar 2013)
- Investors Count 7
All 8 funding rounds of Avitide with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2019 | $10M | Series E | – | – | – |
| Aug 2018 | $6.21M | Series E | – | – | – |
| Jan 2018 | $4M | Series E | – | – | – |
| Jun 2017 | $12M | Series E | – | Sands Capital Ventures | |
| Sep 2016 | Series D | – | – | ||
| Aug 2015 | Series C | – | NeoMed | ||
| Jun 2014 | $3.44M | Series B | – | – | – |
| Mar 2013 | $1.45M | Series A | – | Borealis Ventures |
8 investors in total: 8 institutional.
Investors in Avitide
Avitide has secured backing from 8 investors, including venture fund investors. Prominent investors backing the company include Orbimed, Repligen and Sands Capital Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Growth stage tech & life sciences focused VC Firm investing in Asia and the US | sandscapitalventures.com | Arlington, United States | ||
Private equity investments are made in the UK and US. | mithril.com | Austin, United States | ||
US focused venture capital firm | polarispartners.com | Boston, United States | ||
Stage-agnostic life sciences-focused VC firm investing in North America & Europe | neomed.net | Oslo, Norway | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Venture capital firm investing in seed & series A startups | borealis.vc | Hanover, United States | ||
Venture capital fund focused on early-stage healthcare startups | svhealthinvestors.com | Boston, United States | ||
Products and services for biologic drug manufacturing are supplied. | 1981 | repligen.com | Waltham, United States |
Investor details for Avitide
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Avitide
6 people are tracked at Avitide (4 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Errik Anderson | Co-Founder, former Board Member | Leadership |
Scott Kennedy | Chief Financial Officer and VP of Operations | Leadership |
Grant Espie | Director of Resin Manufacturing | Leadership |
Kelley Kearns, Ph.D. | Director, Downstream Development | Leadership |
Molly North, Ph.D. | Lead Analytical Scientist | Team |
Holly B. | Senior Accountant | Team |
Complete people profiles for Avitide
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Avitide
4 dated milestones of Avitide across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Avitide is founded.
- Funding First funding round of $1.4M.
- Funding Latest funding round, Series E, of $10.0M.
- Exit Acquired by Repligen.
Competitors of Avitide
Avitide has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Sutro Biopharma and Vividion Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform |
Detailed competitors of Avitide
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Avitide
The website of Avitide (avitide.com) receives about 1.3K visits a month.
- Monthly visits1.3K
▼ 32.5% vs previous month
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Avitide (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Avitide
Complete news archive for Avitide
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Avitide
Avitide was founded in 2012 and raised its 1st funding round 1 year after it was founded.
Avitide is headquartered in Lebanon, United States.
Avitide is a funded company, having raised a total of $37.1M across 8 funding rounds to date. The company's 1st funding round was a Series A of $1.45M, raised on Mar 2013.
Avitide was founded in 2012 and is based in Lebanon, United States. Operations focus on the biopharmaceutical sector, where affinity purification solutions are discovered and high-capacity resins are developed for monoclonal antibodies, therapeutic proteins, and recombinant vaccines. Technology access is provided to biopharmaceutical partners, biotechnology firms, and purification product manufacturers via flexible licensing and collaboration arrangements.
Avitide's top competitors include Sutro Biopharma, Avidity Biosciences and Vividion Therapeutics.
Avitide offers AVIPure Resins and Affinity Purification Platform.
Avitide has 8 investors. Key investors include Orbimed, Repligen, Sands Capital Ventures, Mithril, and Polaris Partners.
Yes. Avitide was acquired by Repligen in September 2021.